Skip to content

TETRALOGIC PHARMACEUTICALS CORP: 10-Q filed 2015-08-05

What TETRALOGIC PHARMACEUTICALS CORP reported in its quarterly report filed 2015-08-05 (fiscal Q2 2015): 29 published measures, 82 facts as tagged in accession 0001558370-15-001403.

This filing

Form
10-Q (quarterly report)
Filed
2015-08-05
Fiscal period
fiscal Q2 2015
Accession
0001558370-15-001403 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All TETRALOGIC PHARMACEUTICALS CORP filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2015-06-3099,042,244USD
At 2014-12-31118,291,046USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2015-06-3085,133,747USD
At 2014-12-3184,888,870USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2015-06-3013,908,497USD
At 2014-12-3133,402,176USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2015-06-3012,438,166USD
At 2014-12-3113,073,137USD
At 2014-06-3040,242,102USD
At 2013-12-3155,135,508USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2015-04-01 to 2015-06-30-11,873,047USD91
2015-01-01 to 2015-06-30-24,556,029USD181
2014-04-01 to 2014-06-30-9,354,438USD91
2014-01-01 to 2014-06-30-14,688,505USD181

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2015-01-01 to 2015-06-3050,474USD181
2014-01-01 to 2014-06-30376,165USD181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2015-06-30-150,387,246USD
At 2014-12-31-125,831,217USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2015-04-01 to 2015-06-3023,332,096shares91
2015-01-01 to 2015-06-3023,074,550shares181
2014-04-01 to 2014-06-3022,286,581shares91
2014-01-01 to 2014-06-3022,266,556shares181

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2015-04-01 to 2015-06-3023,370,335shares91
2015-01-01 to 2015-06-3023,116,253shares181
2014-04-01 to 2014-06-3022,350,657shares91
2014-01-01 to 2014-06-3022,333,382shares181

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2015-04-01 to 2015-06-30-0.51USD/shares91
2015-01-01 to 2015-06-30-1.06USD/shares181
2014-04-01 to 2014-06-30-0.42USD/shares91
2014-01-01 to 2014-06-30-0.66USD/shares181

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2015-04-01 to 2015-06-30-0.51USD/shares91
2015-01-01 to 2015-06-30-1.07USD/shares181
2014-04-01 to 2014-06-30-0.42USD/shares91
2014-01-01 to 2014-06-30-0.67USD/shares181

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2015-06-30487,496USD
At 2014-12-31528,476USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2015-01-01 to 2015-06-302,913,844USD181
2014-01-01 to 2014-06-301,642,132USD181

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2015-04-01 to 2015-06-30-11,674,480USD91
2015-01-01 to 2015-06-30-22,304,522USD181
2014-04-01 to 2014-06-30-8,787,101USD91
2014-01-01 to 2014-06-30-14,418,135USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2015-06-3037,223,290USD
At 2014-12-3155,857,363USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2015-04-01 to 2015-06-301,573,070USD91
2015-01-01 to 2015-06-303,136,329USD181
2014-04-01 to 2014-06-30139,446USD91
2014-01-01 to 2014-06-30139,446USD181

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2015-06-305,704,283USD
At 2014-12-315,122,281USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2015-06-301,794,531USD
At 2014-12-311,138,470USD

Goodwill carrying amount

Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.

PeriodValueUnitDays
At 2015-06-3016,902,466USD
At 2014-12-3116,902,466USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2015-04-01 to 2015-06-3011,674,480USD91
2015-01-01 to 2015-06-3022,304,522USD181
2014-04-01 to 2014-06-308,787,101USD91
2014-01-01 to 2014-06-3014,418,135USD181

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2015-04-01 to 2015-06-307,709,798USD91
2015-01-01 to 2015-06-3014,155,991USD181
2014-04-01 to 2014-06-304,864,189USD91
2014-01-01 to 2014-06-307,986,938USD181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2015-06-3023,332,825shares
At 2014-12-3122,334,901shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2015-06-30164,331,927USD
At 2014-12-31159,308,307USD

Net intangible assets excluding goodwill

Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.

PeriodValueUnitDays
At 2015-06-3041,575,516USD
At 2014-12-3141,575,516USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2015-06-301,814,102USD
At 2014-12-312,127,551USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2015-06-303,811,905USD
At 2014-12-313,727,784USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2015-06-302,091,442USD
At 2014-12-311,784,069USD

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2015-04-01 to 2015-06-30-11,865,211USD91
2015-01-01 to 2015-06-30-24,517,398USD181
2014-04-01 to 2014-06-30-9,353,504USD91
2014-01-01 to 2014-06-30-14,687,887USD181

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2015-04-01 to 2015-06-302,883,682USD91
2015-01-01 to 2015-06-306,019,531USD181
2014-04-01 to 2014-06-303,004,912USD91
2014-01-01 to 2014-06-305,513,197USD181

Inspect the source

Entity
TETRALOGIC PHARMACEUTICALS CORP / CIK 0001361248
Captured
SEC response SHA-256
459ce70c5176daae13423155d739231f692bd0099616e958546766a485307349

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001361248.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))